Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Mar;61(3):394–399. doi: 10.1038/bjc.1990.86

Growth inhibition of Friend erythroleukaemia cell tumours in vivo by a synthetic analogue of prostaglandin A: an action independent of natural killer-activity.

S Marini 1, A T Palamara 1, E Garaci 1, M G Santoro 1
PMCID: PMC1971275  PMID: 2328205

Abstract

Prostaglandins of the A series (PGAs) have been previously shown to inhibit the growth and to stimulate the differentiation of Friend erythroleukaemic cells (FLC) in vitro. In the present report we analysed the effect of PGA treatment in vitro on FLC tumorigenicity, and in vivo on FLC proliferation and on natural killer (NK) activity. PGA1 pretreatment of FLC in vitro for 5 days before inoculation into syngeneic mice slightly delayed tumour appearance, but did not significantly alter the pattern of tumour growth or mice survival, indicating that PGA1, at least in the conditions studied, did not affect FLC tumorigenicity. Daily treatment of mice with a long-acting synthetic analogue of PGA2 (16, 16 dimethyl-PGA2-methyl ester, di-M-PGA2) delayed tumour appearance, inhibited tumour growth, as measured by tumour weight and diameter, and increased the median mice survival time by 15-35%, depending on the schedule of treatment. Daily treatment with di-M-PGA2 strongly suppressed NK activity in normal mice but had no significant effect in tumour-bearing immunodepressed mice. PGA treatment of effector or target cells in vitro, or PGA added during the NK assay, had no effect on NK activity. We suggest that the chemotherapeutic effect of PGA is due to a direct action on tumour cell replication rather than to a stimulation of the host NK activity.

Full text

PDF
394

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adolphe M., Giroud J. P., Timsit J., Lechat P. Etude comparative des effets des prostaglandines E1,E2,A2,F1alpha,F1alpha sur la division des cellules HeLa en culture. C R Acad Sci Hebd Seances Acad Sci D. 1973 Jul 30;277(5):537–540. [PubMed] [Google Scholar]
  2. Bankhurst A. D. The modulation of human natural killer cell activity by prostaglandins. J Clin Lab Immunol. 1982 Feb;7(2):85–91. [PubMed] [Google Scholar]
  3. Bregman M. D., Funk C., Fukushima M. Inhibition of human melanoma growth by prostaglandin A, D, and J analogues. Cancer Res. 1986 Jun;46(6):2740–2744. [PubMed] [Google Scholar]
  4. Bregman M. D., Meyskens F. L., Jr Inhibition of human malignant melanoma colony-forming cells in vitro by prostaglandin A1. Cancer Res. 1983 Apr;43(4):1642–1645. [PubMed] [Google Scholar]
  5. Eisenbarth G. S., Lebovitz H. E. Prostaglandin inhibition of cartilage chondromucoprotein synthesis: concept of "intrinsic activity". Prostaglandins. 1974 Jul 10;7(1):11–20. doi: 10.1016/s0090-6980(74)80073-0. [DOI] [PubMed] [Google Scholar]
  6. Favalli C., Garaci E., Santoro M. G., Santucci L., Jaffe B. M. The effect of PGA1 on the immune response in B-16 melanoma-bearing mice. Prostaglandins. 1980 Apr;19(4):587–594. doi: 10.1016/s0090-6980(80)80008-6. [DOI] [PubMed] [Google Scholar]
  7. Friend C., Scher W., Holland J. G., Sato T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci U S A. 1971 Feb;68(2):378–382. doi: 10.1073/pnas.68.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Garaci E., Mastino A., Jezzi T., Riccardi C., Favalli C. Effect of in vivo administration of prostaglandins and interferon on natural killer activity and on B-16 melanoma growth in mice. Cell Immunol. 1987 Apr 15;106(1):43–52. doi: 10.1016/0008-8749(87)90148-1. [DOI] [PubMed] [Google Scholar]
  9. Goodwin J. S., Webb D. R. Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol. 1980 Jan;15(1):106–122. doi: 10.1016/0090-1229(80)90024-0. [DOI] [PubMed] [Google Scholar]
  10. Hanna N., Burton R. C. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J Immunol. 1981 Nov;127(5):1754–1758. [PubMed] [Google Scholar]
  11. Honma Y., Kasukabe T., Hozumi M., Koshihara Y. Regulation of prostaglandin synthesis during differentiation of cultured mouse myeloid leukemia cells. J Cell Physiol. 1980 Sep;104(3):349–357. doi: 10.1002/jcp.1041040308. [DOI] [PubMed] [Google Scholar]
  12. Honn K. V., Bockman R. S., Marnett L. J. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins. 1981 May;21(5):833–864. doi: 10.1016/0090-6980(81)90240-9. [DOI] [PubMed] [Google Scholar]
  13. Hughes-Fulford M., Wu J., Kato T., Fukushima M. Inhibition of DNA synthesis and cell cycle by prostaglandins independent of cyclic AMP. Adv Prostaglandin Thromboxane Leukot Res. 1985;15:401–404. [PubMed] [Google Scholar]
  14. Jaffe B. M., Parker C. W., Philpott G. W. Immunochemical measurement of prostaglandin or prostaglandin-like activity from normal and neoplastic cultured tissue. Surg Forum. 1971;22:90–92. [PubMed] [Google Scholar]
  15. Marini S., Guadagni F., Bonmassar E., Potenza P., Giuliani A. Influence of interferon on the functional expression of natural killer target structures of murine lymphoma cells. Cell Immunol. 1986 Oct 1;102(1):113–125. doi: 10.1016/0008-8749(86)90330-8. [DOI] [PubMed] [Google Scholar]
  16. Narumiya S., Fukushima M. delta 12-Prostaglandin J2, an ultimate metabolite of prostaglandin D2 exerting cell growth inhibition. Biochem Biophys Res Commun. 1985 Mar 29;127(3):739–745. doi: 10.1016/s0006-291x(85)80005-x. [DOI] [PubMed] [Google Scholar]
  17. Olsson I. L., Breitman T. R., Gallo R. C. Priming of human myeloid leukemic cell lines HL-60 and U-937 with retinoic acid for differentiation effects of cyclic adenosine 3':5'-monophosphate-inducing agents and a T-lymphocyte-derived differentiation factor. Cancer Res. 1982 Oct;42(10):3928–3933. [PubMed] [Google Scholar]
  18. Preisler H. D., Bjornsson S., Mori M., Lyman G. H. Inducers of Friend leukaemic cell differentiation in vitro--effects of in vivo administration. Br J Cancer. 1976 Jun;33(6):634–645. doi: 10.1038/bjc.1976.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Santoro M. G., Benedetto A., Jaffe B. M. Effect of endogenous and exogenous prostaglandin E on Friend erythroleukaemia cell growth and differentiation. Br J Cancer. 1979 Mar;39(3):259–267. doi: 10.1038/bjc.1979.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Santoro M. G., Benedetto A., Jaffe B. M. Prostaglandin A1 induces differentiation in Friend erythroleukemia cells. Prostaglandins. 1979 May;17(5):719–727. doi: 10.1016/s0090-6980(79)80043-x. [DOI] [PubMed] [Google Scholar]
  21. Santoro M. G., Crisari A., Benedetto A., Amici C. Modulation of the growth of a human erythroleukemic cell line (K562) by prostaglandins: antiproliferative action of prostaglandin A. Cancer Res. 1986 Dec;46(12 Pt 1):6073–6077. [PubMed] [Google Scholar]
  22. Santoro M. G., Garaci E., Amici C. Prostaglandins with antiproliferative activity induce the synthesis of a heat shock protein in human cells. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8407–8411. doi: 10.1073/pnas.86.21.8407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Santoro M. G., Jaffe B. M. Inhibition of Friend erythroleukaemia-cell tumours in vivo by a synthetic analogue of prostaglandin E2. Br J Cancer. 1979 Apr;39(4):408–413. doi: 10.1038/bjc.1979.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shahabi N. A., Chegini N., Wittliff J. L. Alterations of MCF-7 human breast cancer cell after prostaglandins PGA1 and PGF2 alpha treatment. Exp Cell Biol. 1987;55(1):18–27. [PubMed] [Google Scholar]
  25. Stein-Werblowsky R. The effect of prostaglandin on tumour implantation. Experientia. 1974 Aug 15;30(8):957–959. doi: 10.1007/BF01938385. [DOI] [PubMed] [Google Scholar]
  26. Voth R., Chmielarczyk W., Storch E., Kirchner H. Induction of natural killer cell activity in mice by injection of indomethacin. Nat Immun Cell Growth Regul. 1986;5(6):317–324. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES